Skip to content

Evaluation of Surgery in Elderly With Traumatic Acute SubDural Hematoma

Survival and Quality of Life After Early Surgical Intervention Versus Wait-and-see in Elderly Patients With a Traumatic Acute Subdural Hematoma (ASDH): a Pragmatic Randomized Controlled Trial With Multicenter Parallel Group Design

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04648436
Acronym
RESET-ASDH
Enrollment
0
Registered
2020-12-01
Start date
2022-03-01
Completion date
2023-03-23
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Hemorrhages, Surgery

Keywords

Neurosurgery, Acute subdural hematoma, Traumatic brain injury

Brief summary

Rationale: The rapidly increasing number of elderly (≥ 65 years old) with traumatic brain injury (TBI) is accompanied by substantial medical and economic consequences. An intracranial hematoma, specifically an acute subdural hematoma (ASDH), is the most common injury in elderly with TBI. The surgical versus conservative treatment of this patient group remains an important clinical and moral dilemma, since it is in most cases unclear which treatment leads to a better outcome for the patient. Current guidelines are not based on high-quality evidence and compliance is low, allowing for large treatment variation in both Belgium and the Netherlands for patients with a traumatic ASDH. In addition, elderly are underrepresented in scientific TBI literature and are therefore not included in current guidelines or prognostic models, leading to major uncertainty in (neurosurgical) decision-making for this group. As participants in two large TBI research projects (CENTER-TBI, Net-QuRe), the investigators observe that the uncertainty regarding treatment of elderly with a traumatic ASDH will not be solved by the current ongoing studies. Therefore, they recognize the necessity of undertaking a prospective, randomized, multicenter trial on the (cost-)effectiveness of early surgical hematoma evacuation versus a conservative treatment in elderly with a traumatic ASDH. Objective: To compare the (cost-)effectiveness of early surgical hematoma evacuation versus a conservative treatment in elderly patients with a traumatic ASDH. Study design: A prospective, pragmatic, multicenter, randomized controlled trial (RCT). Study population: Patients ≥ 65 years with at first presentation a GCS ≥ 9 and a traumatic ASDH \>10 mm or a traumatic ASDH \<10 mm and a midline shift \>5 mm, or a GCS \< 9 with a traumatic ASDH \<10 mm and a midline shift \<5 mm without extracranial explanations for the comatose state, for whom clinical equipoise exists regarding the preferred treatment. Intervention: Patients are randomized to either early surgical hematoma evacuation (A) or conservative management on the ICU or the ward (B). In case of neurological deterioration during conservative management, delayed surgery can be performed. The exact neurosurgical technique will be left to the discretion of the surgeons. Main study parameters/endpoints: Functional outcome after 1 year, expressed by the rating on the Extended Glasgow Outcome Scale (GOS-E) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Both treatment strategies are already used in current clinical practice as standard medical care. Therefore, there are no extra risks for patients participating in the study compared to patients outside the study. Study participation adds a minimal burden of three follow-up evaluations by visit in the first year (at 3, 6 and 12 months) and subsequent yearly evaluations by phone or postal until five years after the injury. Future elderly patients with a traumatic ASDH will benefit mostly from this study's results.

Interventions

OTHEREarly neurosurgical hematoma evacuation

Early neurosurgical hematoma evacuation (preferably within 2 hours)

OTHERConservative treatment (best medical management)

Conservative treatment (best medical management) on the ICU or ward

Sponsors

Haaglanden Medisch Centrum
CollaboratorUNKNOWN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
Erasmus Medical Center
CollaboratorOTHER
Elisabeth-TweeSteden Ziekenhuis
CollaboratorOTHER
Medisch Spectrum Twente
CollaboratorOTHER
Radboud Universitair Medisch Centrum
CollaboratorUNKNOWN
Utrecht Universitair Medisch Centrum
CollaboratorUNKNOWN
Universitair Ziekenhuis Leuven
CollaboratorUNKNOWN
Algemeen Ziekenhuis Sint-Jan Brugge
CollaboratorUNKNOWN
Université Libre de Bruxelles
CollaboratorOTHER
Hospital University of Brussels (HUB) Erasme
CollaboratorOTHER
University Hospital, Antwerp
CollaboratorOTHER
Ziekenhuis Oost-Limburg
CollaboratorOTHER
Centre Hospitalier Universitaire de Liege
CollaboratorOTHER
Algemeen Ziekenhuis Delta
CollaboratorUNKNOWN
Funding agencies: ZonMw / KCE (BeNeFIT)
CollaboratorUNKNOWN
Leiden University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Randomized controlled trial with parallel group design

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 65 years * A GCS of ≥ 9 and a traumatic ASDH \>10 mm in diameter or a traumatic ASDH \<10 mm but with a midline shift \>5 mm, or a GCS \<9 and a traumatic ASDH \<10 mm and a midline shift \<5 mm without extracranial explanations for the comatose condition * Clinical equipoise exists (i.e. the responsible neurosurgeon is uncertain about the benefits of either treatment) * Informed consent is obtained or deferred

Exclusion criteria

* Additional epidural hematoma (EDH) or infratentorial (e.g. cerebellar) intracerebral hemorrhage (ICH) * Major traumatic abdominal or thoracic injury (each separately defined as an Abbreviated Injury Scale (AIS) score ≥ 4) or a 'moribund' state at presentation (e.g. bilaterally absent pupillary responses) * Known terminal condition resulting in a life expectancy of less than 1 year

Design outcomes

Primary

MeasureTime frameDescription
Glasgow Outcome Scale Extended (GOS-E)1 yearscale of functional outcome ranging from 1-8 in which a higher score reflects a better recovery

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026